- Home
- TOUR vs KZIA Comparison
TOUR vs KZIA Comparison
Compare TOUR & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TOUR | KZIA |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.0M | 74.1M |
| IPO Year | 2014 | 2002 |
Fundamental Metrics
Financial Performance| Metric | TOUR | KZIA |
|---|---|---|
| Price | $0.71 | $8.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 121.9K | ★ 213.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.74% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.27 | N/A |
| Revenue Next Year | $10.18 | N/A |
| P/E Ratio | $87.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $0.64 |
| 52 Week High | $1.14 | $17.40 |
Technical Indicators
Market Signals| Indicator | TOUR | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 59.10 | 58.79 |
| Support Level | $0.75 | $5.74 |
| Resistance Level | $0.77 | $11.23 |
| Average True Range (ATR) | 0.06 | 1.10 |
| MACD | 0.01 | 0.17 |
| Stochastic Oscillator | 78.75 | 60.84 |
Price Performance
Historical ComparisonAbout TOUR Tuniu Corporation
Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. It offers a large selection of packaged tours, including organized tours and self-guided tours, as well as travel-related services for leisure travelers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.